DarshanTalks Podcast

Send us Fan Mail McKinsey’s vision for Medical Affairs in 2030 envisions profound integration of digital tools, analytical innovation, evidence generation, and leadership transformation. However, this vision faces a critical challenge as recent lawsuit losses against the FDA have shifted the landscape. Previously, Medical Affairs held the exclusive right to share off-label information, but FDA los...

Send us Fan Mail In an ideal world, every patient in clinical trials would feel truly represented. In this video, Darshan Kulkarni outlines three crucial takeaways for collecting diversity data in clinical trials, following guidelines from the FDA.  The guidance emphasizes that one size does not fit all when it comes to race and ethnicity, encouraging detailed categories to embrace the global dive...

Send us Fan Mail We explore the chemical similarities and key differences between brand-name and generic drugs. Learn about: Equivalence in active ingredients, as approved by the FDA. Exceptions: Narrow Therapeutic Index drugs and inactive ingredients. When to consult a doctor before switching brands. Listen to find out if you can save money without sacrificing quality! Support the show www.kulkar...

Send us Fan Mail In this short, we discuss who is responsible for a congruency review in clinical trials. Our guest Istvan Fekete emphasizes that both pharmaceutical companies and research sites share the responsibility for ensuring congruency between the budget, contract, informed consent form (ICF), and coverage analysis. Istvan mentions that a lack of congruency affects both parties and, theref...

Send us Fan Mail Today, we analyze a fictional drug advertisement, identifying and highlighting the nine key unethical and non-compliant elements. - Misleading Information: The claim "The End of High Blood Pressure" suggests that the drug can completely cure high blood pressure, which is likely exaggerated and misleading. 2- Absolute Efficacy Claims: Stating "Proven to work in 100%...

Send us Fan Mail The FDA's announcement of its intention to regulate Lab Developed Tests (LDTs) in line with medical device regulations has sparked concerns among developers, anticipating significant financial implications.  We provide a comprehensive overview of seven strategic approaches for LDT developers to challenge the FDA's regulatory proposal.  Firstly, leveraging the public comm...

Send us Fan Mail eBay found itself as an unexpected marketplace for pill-making equipment, resulting in the company paying a hefty $59 million for facilitating the sale of such equipment. In our video, Darshan delves into this crackdown, shedding light on the hidden underbelly of online retail. The incident highlights the ease with which tools for potentially illegal drug manufacturing can evade e...

Send us Fan Mail In a recent announcement, Elon Musk's company Neuralink revealed the successful implantation of a brain device in a human, pushing the boundaries of neurotechnology.  In our latest short, we discuss key considerations for those venturing into such groundbreaking work.  We emphasize the importance of having a clear investigational plan that outlines study design, methodologies...

Send us Fan Mail In the US v. Facteau case, a recent development adds complexity to the FDA's ongoing struggle with off-label communications, particularly in light of the SIUU guidance and the CFL guidance. The First Circuit ruled against Facteau, emphasizing the distinction from the Caronia case. Unlike Coronia, where the focus was on broader free speech and off-label promotion issues, the U...

Send us Fan Mail We discuss biotech fraud and the pivotal role of a comprehensive legal strategy, especially one that integrates FDA regulatory lawyers. A biotech CEO's admission to securities fraud, misleading investors about a crucial test, underscores the need for stringent legal oversight. At the Kulkarni Law Firm: We’re on the lookout for major red flags,  We ensure press releases not on...

Send us Fan Mail In December 2023, two US senators raised concerns, urging the government to scrutinize the FDA's oversight of medical device recalls, notably amidst the ongoing Phillips Respironics recall. Join us today as we delve into the world of medical device recalls. Facing a recall is every manufacturer's nightmare, but handling it right is paramount. It safeguards patients, pres...

Send us Fan Mail In a congruency review, the primary objective is to ensure alignment across various elements in clinical research. The initial crucial step involves accurately analyzing Medicare coverage, determining designations based on National and Local Coverage Determinations. This forms the foundation for what is billed to the study sponsor and insurance. Any discrepancies at this stage can...

Send us Fan Mail We delve into the growing allure of clinical research sites and organizations for private equity firms. Backed by BPOC, these investments signify more than just single business deals; they are a testament to the increasing interest in fueling healthcare innovation and services. As this trend gains momentum, thorough due diligence becomes crucial in navigating the complexities of t...

Send us Fan Mail In this episode, the focus is on navigating the complex landscape of off-label information sharing, exploring legal aspects in the context of the life sciences industry. Sponsored by the Kulkarni Law Firm, the episode highlights key points: 1. Scientific discussions: Courts are generally cautious about FDA scrutiny in scientific discussions, such as those in academic conferences o...

Send us Fan Mail Darshan discussed crucial updates to the Department of Justice's (DOJ) corporate enforcement policies, particularly impacting FDA-regulated industries like pharmaceuticals and medical devices. The DOJ's focus on mergers and acquisitions (M&A) emphasizes the importance of compliance professionals throughout the entire process. Key Highlights: 1. Corporate Enforcement...

Send us Fan Mail In this podcast, we discuss the legal and regulatory factors for securing approval for your digital speaker program. Key points include  prioritizing audience privacy,  adhering to FTC disclosure regulations,  explicit audience definition,  distinguishing between educational and promotional content, and  navigating health versus product claims.  Link to the detailed podcast:  http...

Send us Fan Mail FDA Issues Crucial Guidance on Prescription Drug Software!  Darshan Kulkarni delves into the FDA's recent guidance on prescription drug-related software. The discussion revolves around three key considerations: 1. software functions,  2. end-user output, and  3. regulatory guidelines.  Notably, the FDA emphasizes distinguishing between functions relying on direct device data...

Send us Fan Mail Insider Exposes crucial missing step in Clinical Trial Agreements activation - Congruency Review Details Revealed! In the clinical trial agreement activation pathway, the journey involves several critical steps. It begins with the signing of the Confidentiality Disclosure Agreement (CDA), followed by the study team's review of the protocol and feasibility goals. Once the stud...

Send us Fan Mail Accelerate your digital speaker program review with these 5 game-changing strategies:  Policy Creation & Training  Pre-reviews  AI-based Reviews   Modular Reviews Applying Quality Learnings Across the Program Dive deeper into each strategy on our podcast!  Watch the full podcast- https://www.youtube.com/watch?v=Ud8jn4c3cCM  Support the show www.kulkarnilawfirm.com

Send us Fan Mail Darshan Kulkarni emphasizes the importance of selecting the right company for clinical trial recruitment. Key considerations include the company's experience and expertise in a specific disease state or area, its reach (national, international, or local), and the associated costs. He warns against the trend of traditional marketing companies entering the clinical trial recrui...

Send us Fan Mail We discuss five key legal and regulatory considerations for a digital sales force: Starting with updates to the Physician Payment Sunshine Act, emphasizing the need for training, robust internal controls, and monitoring.  It also touches on guidance for interactions with healthcare professionals, emphasizing transparency and ethical practices.  The SIUU guidance is discussed, emph...

Send us Fan Mail We explore the crucial aspects outlined by the FTC regarding comparative claims in drug and device advertising.  the paramount importance of transparency in promotional efforts, the pitfalls associated with broad generalizations, and  the need for readiness in the face of scrutiny from both the FDA and the FTC. Providing a valuable intersection of pharmacy, law, and marketing, our...

Send us Fan Mail In this podcast, we explore a groundbreaking shift where clinical research is emerging as a viable care option, known as Clinical Research as a Care Option (CRACO). While the concept seems promising, particularly for patients with conditions like rare diseases or cancer, it introduces a host of concerns. The alignment of Institutional Review Board (IRB) goals with the essence of a...

Send us Fan Mail In this podcast, we discuss artificial intelligence (AI) and machine learning, exploring their pivotal roles in drug development. AI, a fusion of computer science, statistics, and engineering, employs algorithms to perform tasks like learning, decision-making, and prediction. Within the context of drug development, we unravel three significant applications of AI. First, it aids in...

Send us Fan Mail The National Advertising Division (NAD) recently examined a TV ad by Bravecto, comparing its flea and tick prevention product with NexGard's. The ad suggested Bravecto's greater effectiveness, disputed by NexGard. NAD sided with NexGard, emphasizing the need for clear and conspicuous disclosures in comparative advertising.  In a separate case, Google's ads for YouTu...